Discovery of Small Molecule PD ‐ L1 Inhibitors via Optimization of Solvent‐Interaction Region for Cancer Immunotherapy
Chemical Biology & Drug Design · 2025-06 · 105 (6)
DOI: 10.1111/cbdd.70141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 09.06.2025. Verfasst von Binbin Cheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Hubei Polytechnic University, Huangshi, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Small Molecule Libraries, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: the scientific research project of high-level talents in Southern Medical University.
Abstract (Originalsprache)
Despite extensive research, the topic of anti‐PD‐L1 small‐molecule inhibitors remains elusive. Herein, we report the design, synthesis, and bioevaluation of a series of small molecule PD‐L1 inhibitors via optimization of the solvent‐interaction region. Among them, compound GJ19 showed the most potent anti‐PD‐L1 effects with an IC 50 of 32.06 nM in the HTRF (homogenous time‐resolved fluorescence) assay, better than BMS‐202 (IC 50 = 62.1 nM). In addition, the SPR (surface plasmon resonance) assay revealed that GJ19 can effectively bind to human/murine PD‐L1 protein with K D values of 171 and 290 nM, respectively. Furthermore, GJ19 concentration‐dependently promoted HepG2 cell mortality in a co‐culture model of HepG2/hPD‐L1 and Jurkat T/hPD‐1 cells. In the in vivo efficacy studies, GJ19 (intraperitoneal injection, 15 mg/kg) effectively suppressed tumor growth with a TGI of 56.8% in a B16‐F10 melanoma mouse model by activating antitumor immunity. In conclusion, GJ19 represents a potential small molecule inhibitor of PD‐L1, deserving further investigation for tumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Hubei Polytechnic University, Huangshi, China.
- School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou, China.
- Longhua District People's Hospital of Shenzhen, Shenzhen, China.
- Department of Medicine, People's Hospital of Xiangzhou District, Zhuhai, Guangdong, P. R. China.
- Engineering Research Center of Tropical Medicine Innovation and Transformation of Ministry of Education, International Joint Research Center of Human-Machine Intelligent Collaborative for Tumor Precision Diagnosis and T…
- Department of Stomatology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
ORCID-Profile: Jianjun Chen
Förderung
- the scientific research project of high-level talents in Southern Medical University
Zitieren
APA
Cheng, B., Liu, T., Cao, H., Liu, J., Ren, Y., Huang, J., Kong, D., Chen, T., Liu, Y., & Chen, J. (2025). Discovery of Small Molecule PD ‐ L1 Inhibitors via Optimization of Solvent‐Interaction Region for Cancer Immunotherapy. Chemical Biology & Drug Design, 105(6). https://doi.org/10.1111/cbdd.70141
Vancouver
Cheng B, Liu T, Cao H, Liu J, Ren Y, Huang J, et al. Discovery of Small Molecule PD ‐ L1 Inhibitors via Optimization of Solvent‐Interaction Region for Cancer Immunotherapy. Chemical Biology & Drug Design. 2025;105(6). doi:10.1111/cbdd.70141
BibTeX
@article{Cheng2025,
author = {Cheng, Binbin and Liu, Ting and Cao, Hao and Liu, Jin and Ren, Yichang and Huang, Junli and Kong, Dulin and Chen, Ting and Liu, Yong and Chen, Jianjun},
title = {Discovery of Small Molecule PD ‐ L1 Inhibitors via Optimization of Solvent‐Interaction Region for Cancer Immunotherapy},
journal = {Chemical Biology & Drug Design},
year = {2025},
volume = {105},
number = {6},
doi = {10.1111/cbdd.70141}
}
EUVIMED